Evidence map›Paper›PMID 41315792›Full record

ArticleScientific reports2025

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Goki Suda, Masaru Baba, Yoshiya Yamamoto, Sonoe Yoshida, Tetsuhito Muranaka, Takashi Meguro, Katsumi Terashita, Jun Ito, Tomoe Kobayashi, Takaaki Izumi and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Goki SudaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan. gsudgast@pop.med.hokudai.ac.jp.
Masaru BabaJapan Community Health Care Organization (JCHO) Hokkaido Hospital, Sapporo, Hokkaido, Japan.
Yoshiya YamamotoHakodate City Hospital, Hakodate, Hokkaido, Japan.
Sonoe YoshidaHakodate City Hospital, Hakodate, Hokkaido, Japan.
Tetsuhito MuranakaDepartment of Internal Medicine, Wakkanai City Hospital, Wakkanai, Hokkaido, Japan.
Takashi MeguroHokkaido Gastroenterology Hospital, Sapporo, Hokkaido, Japan.
Katsumi TerashitaKeiwakai Ebetsu Hospital, Ebetsu, Hokkaido, Japan.
Jun ItoNational Hospital Organization Hokkaido Medical Center, Sapporo, Hokkaido, Japan.
Tomoe KobayashiTomakomai City Hospital, Tomakomai, Hokkaido, Japan.
Takaaki IzumiSapporo City General Hospital, Sapporo, Hokkaido, Japan.
Tomofumi TakagiJapan Community Health Care Organization (JCHO) Sapporo Hokushin Hospital, Sapporo, Hokkaido, Japan.
Shunichi HosodaKushiro Rosai Hospital, Kushiro, Hokkaido, Japan.
Ren YamadaKushiro Rosai Hospital, Kushiro, Hokkaido, Japan.
Qingjie FuDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Zijian YangDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Daisuke YokoyamaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Takatsugu TanakaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Akimitsu MenoDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Naohiro YasuuraDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Takashi KitagatayaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Masatsugu OharaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Naoki KawagishiDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Masato NakaiDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Takuya ShoDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Koji OgawaDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Naoya SakamotoDepartments of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.

Funding

Japan Agency for Medical Research and Development JP25fk0210126, JP25fk0310545, JP24fk0210121, JP25fk0210142, JP25fk0310551, JP25fk0210123, JP25fk0310535, JP25fk0210157, JP25fk0310543, JP25fk0210172 JP25fk0210174, JP25fk0210143
6 · The paper itself

Abstract

Simplified ("minimal monitoring") pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and effectively with fewer visits remains unclear, and real-world outcomes with sofosbuvir/velpatasvir are scarce. We evaluated effectiveness, safety, and visit frequency in a multicenter cohort. Sixty patients with HCV-infection, with or without compensated liver cirrhosis, received 12 weeks of sofosbuvir/velpatasvir with follow-up to sustained virologic response at 12 weeks post-treatment (SVR12). The visit number was set with no schedule and analyzed post hoc (≤ 3 vs. ≥4 visits). There were 1-8 outpatient visits (median 3). SVR12 was 96.7% by intention-to-treat (ITT; 58/60; 95% CI, 88.6-99.6) and 100% per protocol (57/57; 95% CI, 90.0-100.0). Cure rates were comparable (ITT 95.8-97.2% for ≤ 3 vs. ≥4 visits; p = 1.00; PP 100% in both). Sofosbuvir/velpatasvir was well-tolerated: adverse events were recorded in 10%, none grade ≥ 3, no treatment-related serious events, and no toxicity-related discontinuations. Two patients were lost to follow-up; one who discontinued treatment achieved SVR12. This is the first Japanese real-world evaluation of DAA under simplified monitoring and supports low-burden pathways with high efficacy and safety.

Indexed as

Antiviral AgentsCarbamatesHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsSofosbuvirAdultAgedBenzimidazolesBenzopyransDrug CombinationsEast Asian PeopleFemaleHepacivirusHumansJapanMaleAntiviral AgentsBenzimidazolesBenzopyransCarbamatesDrug CombinationsHeterocyclic Compounds, 4 or More RingsSofosbuvirsofosbuvir-velpatasvir drug combinationvelpatasvirDirect-acting antiviralsHCVJapanProspective cohortSimplified monitoringSofosbuvir/velpatasvir

Identifiers

PMID41315792
PMCPMC12663221

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.